Episode
Episode 179 - Tosh Butt - CEO of Navigator Medicines
- Podcast
- The BioHub - by Avetix
- Published
- May 26, 2026
- Duration seconds
- 1807
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/the-biohub-by-avetix-7252289/episodes/episode-179-tosh-butt-ceo-of-navigator-medicines/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-biohub-by-avetix-7252289/episode-179-tosh-butt-ceo-of-navigator-medicines.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Tosh joins the podcast to talk through Navigator Medicines' bispecific approach to Hidradenitis Suppurativa. Giving us the full picture, from NAV-240's Korean-origins & the 2024 $100million Series A lead by RA Capital & Forbion, to the work that went into their half-life extended next-gen molecule NAV-242 & the speedy clinical development plan that could lead to a step change in HS patient outcomes. We also discuss Tosh's learnings from a career in big pharma across the likes of GSK & AZ, why he had to 'scratch' his biotech 'itch' & the career learnings he's taking into his role at Navigator.